TB-500 (Thymosin Beta-4) is the whole-body repair peptide researchers reach for when the target is not one tissue but all of them. Preclinical work links it to stem-cell mobilization, reduced inflammation, and new blood-vessel growth, and it is usually paired with BPC-157. The evidence base is animal and cell-culture, which the guide states plainly.
- Preclinical models link it to stem-cell mobilization, lower inflammation, and new blood-vessel growth across tissue types.Preclinical (animal/cell culture)
- Upregulates actin-binding via the T4-actin axis.PubMed: TB-500
- In July 2026 the FDA's compounding advisory committee voted 8 to 6 to recommend it for the 503A bulks list (advisory, non-binding, rulemaking still pending).PCAC vote, Jul 2026
- Honest limit: the evidence is animal and cell-culture only, with no published human efficacy trials.Peptide Guide p.100
- The community standard is pairing it with BPC-157 in the Wolverine stack for joint, tendon, and gut work.thepeptidereport